Skip to main content
padlock icon - secure page this page is secure

Reboxetine: its effects as measured by the Social Adaptation Self‐evaluation Scale

Buy Article:

$59.00 + tax (Refund Policy)

The determination of the outcome of treatment for depression is important both for the symptoms of depression and social functioning. The aim of this review is to evaluate the outcome of two clinical trials comparing reboxetine and fluoxetine on depressive symptoms and social functioning. These studies used both conventional measures of outcome such as the Hamilton Rating Scale for Depression (HAM‐D) and the Social Adaptation Self‐evaluation Scale (SASS), a patient‐centred, disease non‐specific scale of social functioning, which was developed for measuring social functioning in depressed people. These findings, set against a background of all studies in which antidepressants have been compared using quality of life instruments, suggest that while some patients may appear to the clinician to have recovered, they may remain less than fully well and differences in selectivity for neurotransmitter systems may play a part in the degree of wellbeing that recovered patients might expect.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: emotional blunting; fluoxetine; quality of life; reboxetine; social functioning

Document Type: Original Article

Publication date: January 1, 2000

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more